Sydney, Feb 20, 2026, 17:48 AEDT — The market has closed.
- Telix shares surged 14.2% after the company posted its full-year results and outlined revenue guidance for 2026.
- Telix booked a 56% jump in 2025 revenue, reaching US$803.8 million. For 2026, the company is guiding group revenue between US$950 million and US$970 million.
- Telix moved to seek European approval for a brain cancer imaging product candidate earlier in the week.
Telix Pharmaceuticals Limited jumped 14.2% to finish the day at A$10.43 on Friday, trading between A$9.49 and A$10.78 along the way, Google Finance data shows. Still, the stock’s got a long climb to reach its 52-week high of A$31.97. (Google)
This shift is notable: Telix, after a tough year for its share price and a rocky opening to 2026, is now working to recalibrate expectations as investors zero in on whether its imaging business can continue to bankroll a larger development pipeline.
The ASX stays closed until Monday, leaving traders eyeing follow-through during the next session. Attention also shifts to the U.S.-listed line as Wall Street gets going later Friday.
Telix reported a 56% jump in 2025 revenue, reaching US$803.8 million, and closed out the year holding US$141.9 million in cash. For 2026, the group is targeting revenue between US$950 million and US$970 million, with research-and-development outlays projected between US$200 million and US$240 million. Adjusted EBITDA came in at US$39.5 million. The bottom line showed a pre-tax loss of US$5.3 million, which management attributed partly to non-cash expenses related to convertible bonds and the RLS acquisition. CEO Dr Christian Behrenbruch described the 2025 results as laying the groundwork for further expansion. (GlobeNewswire)
The guidance underscores an old tension: Telix is ratcheting up development outlays just as investors are pressing for evidence the cash machine stays in gear.
Telix earlier this week announced it had submitted a marketing authorization application in Europe for TLX101-Px, its PET scan agent targeting glioma (brain cancer) imaging—basically, a request to begin selling the product in that region. The company also said a U.S. New Drug Application is next on the list. Telix Precision Medicine CEO Kevin Richardson called the European filing an “important milestone.” Neuroimaging researcher Philipp Lohmann weighed in too, saying the technology “plays a critical role” in guiding treatment, especially when conventional MRI results leave questions. (Telix Pharmaceuticals)
That said, risks are clear enough. Telix faces pressure from regulatory schedules and the realities of manufacturing. If R&D costs climb and revenue growth stalls—or approvals get delayed—profits could come under strain.
